GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » FibroGen Inc (NAS:FGEN) » Definitions » 5-Year Yield-on-Cost %

FibroGen (FibroGen) 5-Year Yield-on-Cost % : 0.00 (As of Apr. 28, 2024)


View and export this data going back to 2014. Start your Free Trial

What is FibroGen 5-Year Yield-on-Cost %?

FibroGen's yield on cost for the quarter that ended in Dec. 2023 was 0.00.


The historical rank and industry rank for FibroGen's 5-Year Yield-on-Cost % or its related term are showing as below:



FGEN's 5-Year Yield-on-Cost % is not ranked *
in the Biotechnology industry.
Industry Median: 1.92
* Ranked among companies with meaningful 5-Year Yield-on-Cost % only.

Competitive Comparison of FibroGen's 5-Year Yield-on-Cost %

For the Biotechnology subindustry, FibroGen's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


FibroGen's 5-Year Yield-on-Cost % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, FibroGen's 5-Year Yield-on-Cost % distribution charts can be found below:

* The bar in red indicates where FibroGen's 5-Year Yield-on-Cost % falls into.



FibroGen 5-Year Yield-on-Cost % Calculation

Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.

Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.

Therefore, Yield-on-Cost of FibroGen is calculated as

Yield-on-Cost=Dividend Yield %*(1+Dividend Growth Rate)^5

FibroGen  (NAS:FGEN) 5-Year Yield-on-Cost % Explanation

Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.


FibroGen 5-Year Yield-on-Cost % Related Terms

Thank you for viewing the detailed overview of FibroGen's 5-Year Yield-on-Cost % provided by GuruFocus.com. Please click on the following links to see related term pages.


FibroGen (FibroGen) Business Description

Traded in Other Exchanges
Address
409 Illinois Street, San Francisco, CA, USA, 94158
FibroGen Inc is a biotechnology company focused on discovering, developing, and commercializing novel therapeutics to treat serious unmet medical needs. The company generates the vast majority of its revenue in Europe, followed by Japan. Virtually all of FibroGen's revenue to date has been generated from its collaboration agreements. FibroGen seeks partners with research, development, and marketing capabilities and other resources that strengthen the company's ability to advance product candidates.
Executives
Jeffrey William Henderson director 7000 CARDINAL PLACE, DUBLIN OH 43017
Enrique A Conterno director, officer: Chief Executive Officer LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285
Thane Wettig officer: Chief Commercial Officer C/O FIBROGEN, INC., 409 ILLINOIS STREET, SAN FRANCISCO CA 94158
Christine Chung officer: SVP, China Operations C/O FIBROGEN, INC., 409 ILLINOIS STREET, SAN FRANCISCO CA 94158
Jeffrey L Edwards director 2525 DUPONT DR, IRVINE CA 92612
Aoife Brennan director 200 SIDNEY STREET, SUITE 320, C/O SYNLOGIC, INC., CAMBRIDGE MA 02139
Benjamin Cravatt director C/O FIBROGEN, INC., 409 ILLINOIS STREET, SAN FRANCISCO CA 94158
Suzanne Blaug director C/O FIBROGEN, INC., 409 ILLINOIS STREET, SAN FRANCISCO CA 94158
Maykin Ho director C/O AGIOS PHARMACEUTICALS, INC., 88 SIDNEY STREET, CAMBRIDGE MA 02139
James A Schoeneck director C/O DEPOMED, INC., 1360 O'BRIEN DRIVE, MENLO PARK CA 94025
Mark Eisner officer: Incoming Chief Medical Officer C/O FIBROGEN, INC., 409 ILLINOIS STREET, SAN FRANCISCO CA 94158
Juan Graham officer: Chief Financial Officer C/O FIBROGEN, INC., 409 ILLINOIS STREET, SAN FRANCISCO CA 94158
Kearns Thomas F Jr director P O BOX 587, WARSAW IN 46581-0587
Pat Controneo officer: VP, Finance and CFO C/O FIBROGEN, INC., 409 ILLINOIS ST.,, SAN FRANCISCO CA 94158
Kalevi Kurkijarvi director C/O FIBROGEN, INC., 409 ILLINOIS ST.,, SAN FRANCISCO CA 94158

FibroGen (FibroGen) Headlines

From GuruFocus

FibroGen Reports First Quarter 2023 Financial Results

By sperokesalga sperokesalga 05-08-2023

FibroGen to Present at Cowen's 43rd Annual Health Care Conference

By sperokesalga sperokesalga 02-27-2023

CFO Juan Graham Sells 1,785 Shares of FibroGen Inc (FGEN)

By GuruFocus Research 06-10-2023